Freeline Therapeutics GmbH (now Ascend Gene and Cell Therapies GmbH) is an indirect 100% subsidiary of Freeline Therapeutics Holdings plc and provides services as well as research and development activities exclusively within the group. The company develops AAV-based systemic gene therapies using a proprietary AAVS3 capsid and has internal capabilities across the entire value chain including CMC, manufacturing, analytics, research and clinical development. The current pipeline includes three internal clinical programs and research programs targeting haemophilia B and lysosomal storage disorders such as Fabry disease and Gaucher disease Type 1. Freeline Therapeutics GmbH reported revenue of EUR 9,669,797 for the 2022 fiscal year, primarily consisting of cost-plus recharges to the parent company.
Entwicklung von Herstellungsmethoden und Analytik für pharmazeutische Produkte im Bereich der Adeno-assoziierten Viren.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) München Local Court, HRB 218160 (as of 2 November 2026)
| Name | Type | City |
|---|---|---|
| Karl Heller | Geschäftsführer(in) | Unterföhring |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 218160 (as of 2 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2022 | €9,669,797 | €739,519 | €7,582,854 | — |
| 2021 | €10,312,606 | €255,633 | €7,754,639 | — |
| 2020 | Rohergebnis€2.2M2 | €104,000 | €6,018,000 | — |
| 2019 | small company1 | €158,271 | €5,020,955 | — |
| 2018 | small company1 | €46,328 | €3,109,335 | — |
| 2017 | small company1 | €37,505 | €2,061,273 | — |
| 2016 | small company1 | €20,225 | €1,921,472 | — |
| 2015 | — | €3,919 | €1,487,206 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) München Local Court, HRB 218160 (as of 2 November 2026)
Eurofins Genomics Europe Pharma and Diagnostics Products & Services Synthesis GmbH
Ebersberg · Herstellung von pharmazeutischen Grundstoffen
zytomanufaktur Dresden GmbH
Dresden · Herstellung von pharmazeutischen Grundstoffen
Dr. Kleine Pharma GmbH
Bielefeld · Herstellung von pharmazeutischen Grundstoffen
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €5,411,708 | 89.4% |
| Material Costs | €32,401 | 0.5% |
| Depreciation | €612,294 | 10.1% |
